CISNET Publications

Breast Working Group

Stout NK, Goldie SJ. Keeping Down the Noise: Common Random Numbers for Disease Simulation Modeling. Health Care Manag Sci In Press.

Stout NK, Rosenberg MA, Trentham-Dietz A, Smith MA, Robinson SM, Fryback DG. Retrospective Cost-Effectiveness Analysis of Screening Mammography. J Natl Cancer Inst 2006;98(11):774-782.

Tosteson ANA, Stout NK, Fryback DG, Acharyya S, Herman B, Hannah H, Pisano E. Cost-Effectiveness of Digital Mammography Breast Cancer Screening: Results from ACRIN DMIST. Ann Intern Med 2008;148(1):1-10.

Cancer Intervention and Surveillance Modeling Network (CISNET) Breast Cancer Collaborators. The Impact of Mammography and Adjuvant Therapy on U.S. Breast Cancer Mortality (1975-2000): Collective Results from the Cancer Intervention and Surveillance Modeling Network.J Natl Cancer Inst Monographs 2006;36:1-126.

Cancer Intervention and Surveillance Modeling Network (CISNET) Breast Cancer Collaborators. Executive Summary. J Natl Cancer Inst Monographs 2006(36):1-2. [Extract]

Feuer EJ. Chapter 1: Modeling the Impact of Adjuvant Therapy and Screening Mammography on U.S. Breast Cancer Mortality Between 1975 and 2000: Introduction to the Problem. J Natl Cancer Inst Monographs 2006(36):2-6. [Extract]

Mariotto AB, Feuer EJ, Harlan LC, Abrams J. Chapter 2: Dissemination of Adjuvant Multiagent Chemotherapy and Tamoxifen for Breast Cancer in the United States Using Estrogen Receptor Information: 1975-1999. J Natl Cancer Inst Monographs 2006(36):7-15. [Abstract]

Rosenberg MA. Chapter 3: Competing Risks to Breast Cancer Mortality. J Natl Cancer Inst Monographs 2006(36):15-9. [Abstract]

Holford TR, Cronin KA, Mariotto AB, Feuer EJ. Chapter 4: Changing Patterns in Breast Cancer Incidence Trends. J Natl Cancer Inst Monographs 2006(36):19-25. [Abstract]

Cronin KA, Mariotto AB, Clarke LD, Feuer EJ. Chapter 5: Additional Common Inputs for Analyzing Impact of Adjuvant Therapy and Mammography on U.S. Mortality. J Natl Cancer Inst Monographs 2006(36):26-9. [Abstract]

Berry DA, Inoue L, Shen Y, Venier J, Cohen D, Bondy M, Theriault R, Munsell MF. Chapter 6: Modeling the Impact of Treatment and Screening on U.S. Breast Cancer Mortality: A Bayesian Approach J Natl Cancer Inst Monographs 2006(36):30-6. [Abstract]

Fryback DG, Stout NK, Rosenberg MA, Trentham-Dietz A, Kuruchittham V, Remington PL. Chapter 7: The Wisconsin Breast Cancer Epidemiology Simulation Model. J Natl Cancer Inst Monographs 2006(36):37-47. [Abstract]

Mandelblatt J, Schechter CB, Lawrence W, Yi B, Cullen J. Chapter 8: The SPECTRUM Population Model of the Impact of Screening and Treatment on U.S. Breast Cancer Trends From 1975 to 2000: Principles and Practice of the Model Methods. J Natl Cancer Inst Monographs 2006(36):47-55. [Abstract]

Tan SYGL, van Oortmarssen GJ, de Koning HJ, Boer R, Habbema JD. Chapter 9: The MISCAN-Fadia Continuous Tumor Growth Model for Breast Cancer. J Natl Cancer Inst Monographs 2006(36):56-65. [Abstract]

Hanin LG, Miller A, Zorin AV, Yakovlev AY. Chapter 10: The University of Rochester Model of Breast Cancer Detection and Survival. J Natl Cancer Inst Monographs 2006(36):66-78. [Abstract]

Lee S, Zelen M. Chapter 11: A Stochastic Model for Predicting the Mortality of Breast Cancer. J Natl Cancer Inst Monographs 2006(36):79-86. [Abstract]

Plevritis SK, Sigal BM, Salzman P, Rosenberg J, Glynn P.Chapter 12: A Stochastic Simulation Model of U.S. Breast Cancer Mortality Trends From 1975 to 2000. J Natl Cancer Inst Monographs 2006(36):86-95. [Abstract]

Clarke LD, Plevritis SK, Boer R, Cronin KA, Feuer EJ. Chapter 13: A Comparative Review of CISNET Breast Models Used To Analyze U.S. Breast Cancer Incidence and Mortality Trends. J Natl Cancer Inst Monographs 2006(36):96-105. [Abstract]

Habbema JD, Tan SYGL, Cronin KA. Chapter 14: Impact of Mammography on U.S. Breast Cancer Mortality, 1975–2000: Are Intermediate Outcome Measures Informative? J Natl Cancer Inst Monographs 2006(36):105-11. [Abstract]

Cronin KA, Feuer EJ, Clarke LD, Plevritis SK.Chapter 15: Impact of Adjuvant Therapy and Mammography on U.S. Mortality From 1975 to 2000: Comparison of Mortality Results From the CISNET Breast Cancer Base Case Analysis. J Natl Cancer Inst Monographs 2006(36):112-21. [Abstract]

Habbema JD, Schechter CB, Cronin KA, Clarke LD, Feuer EJ. Chapter 16: Modeling Cancer Natural History, Epidemiology, and Control: Reflections on the CISNET Breast Group Experience. J Natl Cancer Inst Monographs 2006(36):122-26. [Abstract]

Plevritis SK, Kurian AW, Sigal BM, Daniel BL, Ikeda DM, Stockdale FE, Garber AM. Cost-effectiveness of screening BRCA1/2 mutation carriers with breast magnetic resonance imaging. JAMA 2006 May 24;295(20):2374-84. [Abstract]

Plevritis SK, Salzman P, Sigal BM, Glynn PW. A natural history model of stage progression applied to breast cancer. Stat Med 2006 Apr 5; [Epub ahead of print]. [Abstract]

Stout NK, Rosenberg MA, Trentham-Dietz A, Smith MA, Robinson SM, Fryback DG. Retrospective Cost-effectiveness Analysis of Screening Mammography. J Natl Cancer Inst 2006;98(11):774-782. [Abstract]

Berry DA, Cronin KA, Plevritis SK, Fryback DG, Clarke L, Zelen M, Mandelblatt JS, Yakovlev AY, Habberna JDF, Feuer EJ. Effect of Screening and Adjuvant Therapy on Mortality from Breast Cancer. New Eng J Med 2005 Oct 27;353(17):12-20. [Abstract]

Cronin K.A.,Yu B., Krapcho M., Miglioretti D.L., Fay M.P.,Izmirlian G., Ballard-Barbash R., Geller B.M., Feuer E.J. Modeling The Dissemination Of Mammography In The United States. Cancer Causes Control 2005;16:701-712. [Abstract]

Mandelblatt JS, Schechter CB, Yabroff KR, Lawrence W, Dignam J, Extermann M, Fox S, Orosz G, Silliman R, Cullen J, Balducci L; Breast Cancer in Older Women Research Consortium. Toward optimal screening strategies for older women. J Gen Intern Med 2005 Jun;20(6):487-96. [Abstract]

Rosenberg J, Chia YL, Plevritis S. The effect of age, race, tumor size, tumor grade, and disease stage on invasive ductal breast cancer survival in the U.S. SEER database. Breast Cancer Res Treat Jan 2005;89(1):47-54. [Abstract]

Shen Y, Yang Y, Inoue LY, Munsell MF, Miller AB, Berry DA. Role of detection method in predicting breast cancer survival: analysis of randomized screening trials. J Natl Cancer Inst 17 Aug 2005;97(16):1195-203. [Abstract]

Zorin AV, Edler L, Hanin LG, Yakovlev AY. Estimating the natural history of breast cancer from bivariate data on age and tumor size at diagnosis. In: Edle L, Kitsos CP, editors. Recent Advances in Quantitative Methods for Cancer and Human Health Risk Assessment. New York: Wiley; 2005. p. 317-27.

Andersen LD, Remington PL, Trentham-Dietz A, Robert S. Community trends in the early detection of breast cancer in Wisconsin, 1980-1998. Am J Prev Med Jan 2004;26(1):51-5. [Abstract]

Boer R, Plevritis S, Clarke L. Diversity of model approaches for breast cancer screening: a review of model assumptions by the Cancer Intervention and Surveillance Network (CISNET) Breast Cancer Groups. Stat Methods Med Res 2004 Dec;13(6):525-38. [Abstract]

Chia L, Salzman P, Plevritis SK, Glynn PW. Simulation-based parameter estimation for complex models: a breast cancer natural history modeling illustration. Stat Methods Med Res 2004 Dec;13(6):507-24. [Abstract]

Hanin LG, Yakovlev AY. Multivariate distributions of clinical covariates at the time of cancer detection. Stat Methods Med Res 2004 Dec;13(6):457-89. [Abstract]

Hu P, Zelen M. Planning of randomized early detection trials. Stat Methods Med Res 2004;13:491-506. [Abstract]

Lee S, Huang H, Zelen M. Early detection of disease and the scheduling of examinations. Stat Methods Med Res 2004;13:443-56. [Abstract]

Mandelblatt J, Schechter CB, Yabroff KR, Lawrence W, Dignam J, Muennig P. Benefits and costs of interventions to improve breast cancer outcomes in African American women. J Clin Oncol 2004 Jul 1;22(13):2554-66. [Abstract]

Lee SJ, Zelen M. Modeling the early detection of breast cancer. Ann Oncol 2003;14:1199-1202. [Abstract]

Mandelblatt J, Saha S, Teutsch S. The cost-effectiveness of screening mammography beyond age 65 years: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med 2003 Nov 18;139(10):835-42. [Abstract]

Polsky D, Mandelblatt JS, Weeks JC, Venditti L, Hwang YT, Glick HA, Hadley J, Schulman KA. Economic evaluation of breast cancer treatment: considering the value of patient choice. J Clin Oncol 15 Mar 2003;21(6):1139-46. [Abstract]

Stout NK, Rosenberg MA, Fryback DG. Does Diagnosis by Screening Mammography Lead to a Gain in Life Expectancy for Women with Breast Cancer and if so How Much? Med Decis Making 2003;23(6):552.

Stout NK, Rosenberg MA, Remington PL, Trentham-Dietz A, Fryback DG. Can routine screening really reduce breast cancer mortality by 40-60%. Med Decis Making 2003;23(6):559.

Tan SYGL, Oortmarssen GJ, van Piersma N. Estimating parameters of a microsimulation model for breast cancer screening using the score function method. Ann Oper Res 2003;119:43-61. [Abstract]

Yabroff KR, Washington KS, Leader A, Neilson E, Mandelblatt J. Is the promise of cancer-screening programs being compromised? Quality of follow-up care after abnormal screening results. Med Care Res Rev Sep 2003;60(3):294-331. [Abstract]

Hanin L. Identification problem for stochastic models with application to carcinogenesis, cancer detection and radiation biology. Discrete Dynamics in Nature and Society 2002;7:177-89.

Lee SJ, Zelen M. Statistical models for screening: planning public health programs. In: Beam C, editor. Biostatistical applications in cancer research. Boston: Kluwer Academic Publishers; 2002. p. 19-36. [Abstract]

Mariotto A, Feuer EJ, Harlan LC, Wun LM, Johnson KA, Abrams J. Trends in use of adjuvant multi-agent chemotherapy and tamoxifen for breast cancer in the United States: 1975-1999. J Natl Cancer Inst 2002 Nov 6;94(21):1626-34. [Abstract]

Zelen M, Lee SJ. Models and the early detection of disease: methodological consideration. In: Beam C, editor. Biostatistical applications in cancer research. Boston: Kluwer Academic Publishers; 2002. [Abstract]

Bartoszynski R, Edler L, Hanin L, Kopp-Schneider A, Pavlova L, Tsodikov A, Zorin A, Yakovlev AY. Modeling cancer detection: tumor size as a source of information on unobservable stages of carcinogenesis. Math Biosci 2001 Jun;171(2):113-42. [Abstract]

Hanin LG, Tsodikov AD, Yakovlev AY. Optimal regimens of cancer screening. Math Comput Model 2001;33:1419-30. [Abstract]

Saha S, Hoerger TJ, Pignone MP, Teutsch SM, Helfand M, Mandelblatt JS; Cost Work Group, Third US Preventive Services Task Force. The art and science of incorporating cost effectiveness into evidence-based recommendations for clinical preventive services. Am J Prev Med 2001 Apr;20(3 Suppl):36-43. [Abstract]

Shen Y, Zelen M. Screening sensitivity and sojourn time from breast cancer early detection clinical trials: mammograms and physical examinations. J Clin Oncol 2001 Aug 1;19(15):3490-9. [Abstract]

Yabroff KR, O'Malley A, Mangan P, Mandelblatt J. Inreach and outreach interventions to improve mammography use. J Am Med Womens Assoc 2001;56(4):166-73, 188. [Abstract]

Return to top

Colorectal Working Group

Jeon J, Meza R, Moolgavkar SH, Luebeck EG. Evaluation of screening strategies for pre-malignant lesions using a biomathematical approach. Math Biosci 2008:213;56-70. [Abstract]

Miglioretti DL, Brown ER. A marginalized diffusion model for estimating age at first lower endoscopy use from current-status data. Journal of the Royal Statistical Society, Series C (Applied Statistics) 2008;57(1):61-74. [Abstract]

Rutter CM, Miglioretti DM, Yu, O. A hierarchical non-homogeneous Poisson model for meta-analysis of adenoma counts. Statistics in Medicine, 2007; 26:98-109. [Abstract]

Vogelaar I, van Ballegooijen M, Schrag D, Boer R, Winawer SJ, Habbema JD, Zauber AG. How much can current interventions reduce colorectal cancer mortality in the U.S.: mortality projections for scenarios of risk-factor modification, screening, and treatment. Cancer 2006 Aug 24;107(7):1624-33. [Abstract]

Winawer SJ, Zauber AG, Fletcher RH, Stillman JS, O'Brien MJ, Levin B, Smith RA, Lieberman DA, Burt RW, Levin TR, Bond JH, Brooks D, Byers T, Hyman N, Kirk L, Thorson A, Simmang C, Johnson D, Rex DK, US Multi-Society Task Force on Colorectal Cancer, American Cancer Society. Guidelines for colonoscopy surveillance after polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer and the American Cancer Society. Gastroenterology May 2006;130(6):1872-85. [Abstract]

Winawer SJ, Zauber AG, Fletcher RH, Stillman JS, O'brien MJ, Levin B, Smith RA, Lieberman DA, Burt RW, Levin TR, Bond JH, Brooks D, Byers T, Hyman N, Kirk L, Thorson A, Simmang C, Johnson D, Rex DK. Guidelines for colonoscopy surveillance after polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer and the American Cancer Society. CA Cancer J Clin 2006 56(3):143-59; quiz 184-5.

de Visser M, van Ballegooijen M, Bloemers SM, van Deventer SJ, Jansen JB, Jespersen J, Kluft C, Meijer GA, Stoker J, de Valk GA, Verweij MF, Vlems FA. Report on the Dutch consensus development meeting for implementation and further development of population screening for colorectal cancer based on FOBT. Cell Oncol 2005;27(1):17-29. [Abstract]

Loeve F, Boer R, Zauber AG, van Balleooijen M, van Oortmarssen GJ, Winawer SJ, Habbema JD. National Polyp Study data: evidence for regression of adenomas. Int J Cancer 2004;111:633-9. [Abstract]

Loeve F, van Ballegooijen M, Boer R, Kuipers EJ, Habbema JDF. Colorectal cancer risk in adenoma patients: a nation-wide study. Int J Cancer 2004:111(1):147-41. [Abstract]

Schrag D. The price tag on progress-chemotherapy for colorectal cancer. New Eng J Med 2004; 351(4):317-9. [Abstract]

Return to top

Lung Working Group

Levy DT, Bauer J, Lee H-R. The use of simulation models to examine the effect of public policies in a dynamic social system. Am J Public Health (in press).

Meza R, Hazelton WD, Colditz GA, Moolgavkar SH. Analysis of lung cancer incidence in the nurses' health and the health professionals' follow-up studies using a multistage carcinogenesis model. Cancer Causes Control Apr 2008;19(3):317-28. [Abstract]

Levy DT, Ross H, Powell L, Bauer J, Lee HR. The role of public policies in reducing smoking prevalence in Arizona: results from the Arizona tobacco policy simulation model. J Public Health Manag Pract 2007 Jan-Feb;13(1):59-67. [Abstract]

Levy D, Mumford E, Cummings M, Gilpin B, Giovino G, Hyland A, Sweanor D, Warner K. The potential impact of a low-nitrosamine smokeless tobacco product on cigarette smoking in the United States: Estimates of a panel of experts. Addict Behav 2006 Jul;31(7):1190-200. Epub 2005 Oct 26. [Abstract]

Clements MS, Armstrong BK, Moolgavkar SH. Lung cancer rate predictions using generalized additive models. Biostatistics 2005 Oct;6(4):576-89. Epub 2005 Apr 28. [Abstract]

Gorlova O, Peng B, Yankelevitz D, Henschke C, Kimmel M. Estimating the growth rates of primary lung tumours from samples with missing measurements. Stat Med 2005 Apr 15;24(7):1117-34. [Abstract]

Hazelton WD, Clements MS, Moolgavkar SH. Multistage carcinogenesis and lung cancer mortality in three cohorts. Cancer Epidemiol Biomarkers Prev 2005 May;14(5):1171-81. [Abstract]

Levy DT, Nikolayev L, Mumford EA. Recent trends in smoking and the role of public policies: results from the SimSmoke Tobacco Control Policy Simulation Model. Addiction 2005;10(10):1526-37. [Abstract]

Levy DT, Nikolayev L, Mumford EA, Compton C. The Healthy People 2010 smoking prevalence and tobacco control objectives: results from the SimSmoke tobacco control policy simulation model (United States). Cancer Causes Control 2005 May;16(4):359-71. [Abstract]

Levy DT, Mumford EA, Cummings KM, Gilpin EA, Giovino G, Hyland A, Sweanor D, Warner KE. The relative risks of a low-nitrosamine smokeless tobacco product compared with smoking cigarettes: estimates of a panel of experts. Cancer Epidemiol Biomarkers Prev 2004 Dec;13(12):2035-42. [Abstract]

Zeliadt SB, Penson DF, Albertsen PC, Concato J, Etzioni RD. Race independently predicts prostate specific antigen testing frequency following a prostate carcinoma diagnosis. Cancer 1 Aug 2003;98(3):496-503. [Abstract]

Levy DT, Chaloupka F, Gitchell J, Mendez D, Warner KE. The use of simulation models for the surveillance, justification and understanding of tobacco control policies. Health Care Manag Sci Apr 2002;5(2):113-20. [Abstract]

Return to top

Prostate Working Group

Tsodikov A, Garibotti G. Profile information matrix for nonlinear transformation models. Lifetime Data Anal 2006 Oct 5; [Epub ahead of print]. [Abstract]

Tsodikov A, Szabo A, Wegelin J. A population model of prostate cancer incidence. Stat Med 2006 Aug 30;25(16):2846-66. [Abstract]

Draisma G, Postma R, Schröder FH, van der Kwast TH, de Koning HJ. Gleason score, age and screening: modeling dedifferentiation in prostate cancer. Int J Cancer 2006 Jul 20; [Epub ahead of print]. [Abstract]

Feuer EJ, Etzioni R, Cronin KA, Mariotto A. The use of modeling to understand the impact of screening on U.S. mortality: examples from mammography and PSA testing. Stat Methods Med Res 2004 Dec;13(6):421-42. [Abstract (appears in Breast Working Group)]

Inoue L, Etzioni R, Slate E, Morrell C. Combining logitudinal studies of PSA. Biostat 2004;5:483-500. [Abstract]

Shaw PA, Etzioni R, Zeliadt SB, Mariotto A, Karnofski K, Penson DF, Weiss NS, Feuer EJ. An ecologic study of prostate-specific antigen screening and prostate cancer mortality in nine geographic areas of the United States. Am J Epidemiol 2004 Dec 1;160(11):1059-69. [Abstract]

Zeliadt SB, Potosky AL, Etzioni R, Ramsey SD, Penson DF. Racial disparity in primary and adjuvant treatment for nonmetastatic prostate cancer: SEER-Medicare trends 1991 to 1999. Urology 2004 Dec;64(6):1171-6. [Abstract]

Etzioni R, Berry KM, Legler J, Shaw P. Prostate-specific antigen testing in black and white men: an analysis of Medicare claims from 1991-1998. Urology 2002 Feb;59(2):251-255. [Abstract]

Etzioni R, Penson DF, Legler JM, di Tommaso D, Boer R, Gann PH, Feuer EJ. Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst 2002 Jul 3;94(13):981-90. [Abstract]

Return to top

General Methods

Hanin L, Yakovlev A. Identifiability of the joint distribution of age and tumor size at detection in the presence of screening. Math Biosci Aug 2007;208(2):644-57. [Abstract]

Hanin LG, Pavlova LV. Optimal regimens of cancer screening. In: Edler L, Kitsos CP, eds. Recent Advances in Quantitative Methods in Cancer and Human Health Risk Assessment. New York: Wiley; Jun 2006. p. 177-191.

Holford TR. Approaches to fitting age-period-cohort models with unequal intervals. Stat Med 2006 Mar 30;25(6):997-993. [Abstract]

Pignone M, Saha S, Hoerger T, Lohr KN, Teutsch S, Mandelblatt J. Challenges in systematic reviews of economic analyses. Ann Intern Med 21 Jun 2005;142(12 Pt 2):1073-9. [Abstract]

Shen Y, Zelen M. Robust modeling in screening studies: estimation of sensitivity and preclinical sojourn time distribution. Biostatistics 2005; 6:604-14. [Abstract]

Zelen M. Risks of cancer and families. J Natl Cancer Inst 2005; 97:1556-7.

Boucher KM, Asselain B, Tsodikov AD, Yakovlev AY. Semiparametric versus parametric regression analysis based on the bounded cumulative hazard model: An application to breast cancer recurrence. In: Nikulin MS, Balakrishnan N, Mesban M, Limnios N, eds. Parametric and Semiparametric Models with Applications to Reliability, Survival Analysis, and Quality of Life. Boston, MA: Birhauser; 24 Jun 2004. p. 399-418.

Broët P, Tsodikov A. De Rycke Y, Moreau T. Two-sample statistics for testing the equality of survival functions against improper semi-parametric accelerated failure time alternatives: An application to the analysis of a breast cancer clinical trial. Lifetime Data Anal 2004;10:103-20. [Abstract]

Davidov O, Zelen M. Overdiagnosis in early detection programs. Biostatistics 2004;5:603-13. [Abstract]

Feuer EJ, Boer R, Holford TR. Developing and comparing population models for the early detection of cancer. Stat Meth Med Res 2004;13:419-20.

Feuer EJ, Etzioni R, Cronin KA, Mariotto A. The use of modeling to understand the impact of screening on U.S. mortality: examples from mammography and PSA testing. Stat Methods Med Res 2004 Dec;13(6):421-42. [Abstract]

Tsodikov A. Generalized self-consistency methods for cure models. INSERM Workshop 154, 2004. [Abstract]

Zelen M. Forward and backward recurrence times and length biased sampling: Age specific models. Lifetime Data Anal 2004; 10:325-34. [Abstract]

Davidov O, Zelen M. The theory of case-control studies for early detection programs. Biostatistics 2003;4:411-21. [Abstract]

Tsodikov A. Semiparametric models: a generalized self-consistency approach. Journal of the Royal Statistical Society 2003;65:759-74. [Abstract]

Tsodikov AD, Ibrahim JG,Yakovlev AY. Estimating cure rates from survival data: an alternative to two-component mixture models. J Amer Statist Assoc 2003;98:1063-1078.[Abstract]

Gregori G, Hanin L, Luebeck G, Moolgavkar S, Yakovlev A. Testing goodness of fit for stochastic models of carcinogenesis. Math Biosci Jan 2002;175(1):13-29. [Abstract]

Hu P, Zelen M. Experimental design issues for the early detection of disease: novel designs. Biostatistics 2002; 3:299-313. [Abstract]

McCulloch CE, Lin H, Slate EH, Turnbull BW. Discovering subpopulation structure with latent class mixed models. Stat Med 15 Feb 2002;21(3):417-29. [Abstract]

Shen Y, Wu D, Zelen M. Testing the independence of two diagnostic tests. Biometrics Dec 2001;57(4):1009-17. [Abstract]

Return to top